top of page
A L T I T U D E
Life Science Ventures
HOME
ABOUT
PORTFOLIO
Fund IV
Fund III
Fund II
Historical
TEAM
NEWS
CONTACT
More
Use tab to navigate through the menu items.
Companies in the News
Dec 8, 2023
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant...
bottom of page
